Advancing Breast Cancer Screening With A Non-invasive Blood Test
About BCAL Diagnostics
BCAL Diagnostics Limited (ASX: BDX) is an Australian biotechnology company dedicated to advancing early and accurate breast cancer diagnosis.
BCAL Diagnostics has transitioned from an R&D-focused company to a revenue-generating diagnostic service business, with commercial operations underway through its NATA accredited laboratory in Sydney. The Company is now focused on scaling test delivery and building market adoption while continuing to invest in R&D to expand its product pipeline, drive innovation, and unlock long-term growth opportunities.
Our innovative, non-invasive blood test, BREASTEST plus™ is designed to complement existing breast screening. Developed in partnership with clinicians, BREASTEST plus™ provides additional diagnostic information—particularly for women with dense breast tissue—to support greater confidence in clinical decision-making and breast health management.
The Board of BCAL Diagnostics is committed to transparency, integrity, and accountability, ensuring our governance framework supports long-term growth and sustainability.
A strong, values-based governance structure is fundamental to our company, guiding ethical decision-making and responsible business practices. We align with best practice principles and the ASX Corporate Governance Council’s recommendations to uphold these standards.
For more details, download our key policies below.
